Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-3866 in Hepatic Impairment
NCT03295266Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-3866 in gram-negative bacterial infections (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-time Curve of MK-3866 From Time 0 to Infinity, Area Under the Concentration-time Curve of MK-3866 From Time 0 to Last Quantifiable Concentration and 6 more. Started Dec 2017; status: terminated.
02
Drugs
MK-3866
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT03295266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295266.